Figure S1: Doses given and DLTs experienced in the dose escalation and dose expansion cohorts from A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2− Advanced Breast Cancer

A total of 45 patients were recruited and four to six patients were allocated to cohorts to receive escalating doses of AZD9496. In the BID cohorts, patients received QD dosing on Day 1 and BID dosing thereafter. Six patients entered the expansion cohort, receiving AZD9496 250 mg BID. BID=twice daily, DLT=dose-limiting toxicity; n=number of patients included; LFT=liver function tests; QD=once daily.